Tiziana Life Sciences PLC Directorate Change (2847P)
February 07 2019 - 1:00AM
UK Regulatory
TIDMTILS
RNS Number : 2847P
Tiziana Life Sciences PLC
07 February 2019
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Directorate Change
New York/London, 7 February 2019 - Tiziana Life Sciences plc
(Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the
discovery and development of innovative therapeutics for
inflammation and oncology indications, today announces that
Riccardo Dalla-Favera MD has resigned from his role as
Non-Executive Director of the Company. The Company is grateful to
Dr Favera for his time, expertise and commitment to the
Company.
The person who arranged for release of this announcement on
behalf of the Company was Tiziano Lazzaretti, Chief Financial
Officer of the Company.
About Tiziana Life Sciences
Tiziana is a UK biotechnology company that focuses on the
discovery and development of novel molecules to treat human disease
in oncology and immunology. In addition to milciclib, the Company
is also developing Foralumab for liver diseases. Foralumab is the
only fully human anti-CD3 mAbs in clinical development in the
world. This compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBS),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
inflammatory bowel disease (IBD), psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
For more information go to
http://www.tizianalifesciences.com
Contacts:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner +44 (0)20 7213 0880
Stockdale Securities (Nominated broker)
Antonio Bossi / Andy Crossley +44 (0)20 7601 6125
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGUQGPUPBGCQ
(END) Dow Jones Newswires
February 07, 2019 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024
